February 15, 2018 – STAAD, SWITZERLAND and TEL AVIV, ISRAEL – Only last August, Ramot at Tel Aviv University and BIOSYNTH AG announced their joint development work on novel detection molecules. The subject of this cooperation is the AquaSpark™ technology for chemiluminescence-based markers. They represent state-of-the-art technology and considerably improve the detection limits of diagnostic tests in comparison to existing conventional systems. Tel Aviv University’s Business Engagement Center, Ramot has filed a series of probes under the trademark name AquaSpark™. Biosynth received a license to manufacture and sell the AquaSpark™ probes.

Today, Biosynth announced that just after six months of intensive work together the first products have been launched. These are the most sensitive substrates for the detection of phosphatase activity on the world market today. Phosphatase is a widely-used enzyme in clinical diagnostics and basic research, a crucial component in antibody-based assays to visualize marker proteins for many diseases. Biosynth has launched two AquaSpark™ phosphatase substrates with different properties and price tags. These two options allow immunoassay manufacturers and research labs to achieve hitherto unique results in their applications.

About Biosynth: Biosynth is an accomplished player with a successful history in the field of biochemicals for the diagnostics, pharmaceutical and chemical industries as well as food and environmental analysis. Biosynth ‘s own biology and chemistry labs constantly drive the further development of molecules for the sensitive detection of pathogens. In recent years Biosynth has successfully introduced innovative chromogenic, fluorogenic and luminescence-based systems into the field. The Swiss-based organization has branches in the USA, China and the EU as well as a worldwide distribution network that reaches the entire diagnostics industry. Biosynth, with its product offering of over 100’000 substances is a competent partner for industrial as well as research customers. www.biosynth.com

https://campaign.biosynth.com/e…